Linnaeus Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics that target a novel G protein-coupled receptor, known as GPER, or GPR30. The company was formed and launched in partnership with the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI). The company's lead molecule, LNS8801, is in the final stages of preclinical development. The company expects to begin its phase 1 clinical program in the near-term. In addition to developing GPER agonists, Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/17/19 | $12,000,000 | Series B |
Kairos Ventures Penn Medicine | undisclosed |
